Researchers have identified a receptor protein known as CHRM1 as a key player in prostate cancer cells' resistance to docetaxel, a commonly-used chemotherapy drug to treat advanced cancer that has spread beyond the prostate.
Jan 22, 2024
0
15
Survival for advanced stomach and oesophagael cancer patients increases by 40 per cent when treated with the chemotherapy drug, Docetaxel – providing evidence to prescribe it as a second-line treatment, according to the ...
Jan 23, 2013
0
0
Nivolumab has been approved since April 2016 as a checkpoint inhibitor for the treatment of adults with locally advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) who have already undergone chemotherapy. ...
Aug 18, 2016
0
1
The first direct comparison of treating non-squamous lung cancer with either pemetrexed or docetaxel in addition to cisplatin has shown that the two combinations achieve similar progression-free survival, although docetaxel ...
Sep 27, 2014
0
0
A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone ...
Nov 28, 2012
0
0
The nanoparticle drug BIND-014 is effective against multiple solid tumors, according to results generated by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, and presented today at the American ...
Apr 9, 2013
0
0
The U.S. Food and Drug Administration today approved a new drug to treat non-small-cell lung cancer (NSCLC), offering patients new hope in fighting this difficult disease. Lung cancer is expected to lead to over 150,000 deaths ...
Dec 15, 2014
0
0
For patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen deprivation therapy (ADT), and doublet therapy ...
Apr 12, 2023
0
9
(Medical Xpress)—Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells ...
Dec 11, 2012
0
0
Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid. (1)
Sep 8, 2017
0
4
